• Home
  • News
  • Analysis
  •  
    Regions
    • Australasia
    • Southeast Asia
    • Greater China
    • North Asia
    • South Asia
    • North America
    • Europe
    • Central Asia
    • MENA
  •  
    Funds
    • LPs
    • Buyout
    • Growth
    • Venture
    • Renminbi
    • Secondary
    • Credit/Special Situations
    • Infrastructure
    • Real Estate
  •  
    Investments
    • Buyout
    • Growth
    • Early stage
    • PIPE
    • Credit
  •  
    Exits
    • IPO
    • Open market
    • Trade sale
    • Buyback
  •  
    Sectors
    • Consumer
    • Financials
    • Healthcare
    • Industrials
    • Infrastructure
    • Media
    • Technology
    • Real Estate
  • Events
  • Chinese edition
  • Data & Research
  • Weekly Digest
  • Newsletters
  • Sign in
  • Events
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)870 240 8859

      Email: customerservices@incisivemedia.com

      • Sign in
     
      • Saved articles
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • RSS
    • Twitter
    • LinkedIn
    • Newsletters
  • Free Trial
  • Subscribe
  • Weekly Digest
  • Chinese edition
  • Data & Research
    • Latest Data & Research
      2023-china-216x305
      Regional Reports

      The reports review the year's local private equity and venture capital activity and are filled with up-to-date data and intelligence on fundraising, investments, exits and M&A. The regional reports also feature information on key companies.

      Read more
      2016-pevc-cover
      Industry Review

      Asian Private Equity and Venture Capital Review provides an independent overview of the private equity, venture capital and M&A activities in the Asia region. It delivers insights on investments made, capital raised, sector specific figures and more.

      Read more
      AVCJ Database

      AVCJ Database is the ultimate link between Asian dealmakers and those who provide advisory, financial, legal and technological services to the private equity, venture capital and M&A industries. It is packed with facts and figures on more than 153,000 companies and almost 117,000 transactions.

      Read more
AVCJ
AVCJ
  • Home
  • News
  • Analysis
  • Regions
  • Funds
  • Investments
  • Exits
  • Sectors
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)870 240 8859

    Email: customerservices@incisivemedia.com

    • Sign in
 
    • Saved articles
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 

Citic Private Equity

CITIC PE invests in China's New Journey Hospital

CITIC Private Equity (CITIC PE) has invested an undisclosed sum in New Journey Hospital Group, a Chinese cancer hospital operator.

  • Greater China
  • 31 March 2016
PE investors to exit China's Happigo Home Shopping

Hony Capital, CITIC Private Equity and Sequoia Capital are set to exit Happigo Home Shopping, a Shenzhen-listed online and TV shopping subsidiary of Hunan TV.

  • Greater China
  • 17 March 2016
PE-backed BeiGene gains 18% on debut after $158m IPO

BeiGene, a Chinese cancer drug developer backed by Hillhouse Capital and CITIC Private Equity, closed up 18% on its first day of trading on NASDAQ following a $158.4 million IPO.

  • Greater China
  • 04 February 2016
CITIC PE-owned online finance platforms raise $65m

Maidai Licai and China Top Credit, two Chinese online finance platforms wholly-owned by CITIC Private Equity, have raised RMB420 million ($65 million) from their parent company and other strategic investors.

  • Greater China
  • 11 December 2015
Australia's Archer agrees Healthe Care sale to China-based Luye

Archer Capital has agreed to sell Healthe Care, Australia’s third-largest private hospital group, to China-based Luye Medical Group, for $688 million. CITIC Private Equity is a shareholder in the company’s Hong Kong-listed affiliate, Luye Pharma.

  • Exits
  • 07 December 2015
Biosensors agrees to CITIC Private Equity buyout

The board of Singapore-listed medical devices manufacturer Biosensors International has accepted a buyout offer from CITIC Private Equity that values the company at approximately S$1.4 billion ($996 million).

  • Greater China
  • 06 November 2015
CITIC PE seeks full ownership of Biosensors International

CITIC Private Equity has submitted a buyout offer for Biosensors International, a Singapore-listed medical devices manufacturer in which it already holds close to a 20% stake.

  • Buyouts
  • 29 October 2015
PE-backed China drug developer files for US IPO

BeiGene, a Chinese company backed by the likes of Hillhouse Capital and CITIC Private Equity that develops drugs to treat cancer, has filed for an IPO in the US.

  • Greater China
  • 20 October 2015
ManpowerGroup teams up with CITIC PE to expand China business

CITIC Private Equity (CITIC PE) has formed a joint venture with Shanghai-based recruiting giant ManpowerGroup to expand the company's business in greater China.

  • Greater China
  • 14 September 2015
CITIC PE-backed 3SBio IPO raises $711m in Hong Kong IPO

CITIC Private Equity has made a partial exit from Chinese biotech player 3SBio as the company raised HK$5.51 billion ($711 million), two years after leaving NASDAQ in a take-private deal.

  • Exits
  • 08 June 2015
GIC, BlackRock cornerstone CITIC PE-backed 3SBio's IPO

GIC Private and BlackRock have joined four other investors to cornerstone Chinese biotech pharmaceutical developer 3SBio's relisting in Hong Kong, two years after it was taken off NASDAQ by CITIC Private Equity.

  • Greater China
  • 28 May 2015
China's BeiGene raises $97m from PE investors

BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.

  • Greater China
  • 14 May 2015
CITIC Private Equity raises $1.3b for second US dollar fund

CITIC Private Equity has closed it second US dollar-denominated China fund with just under $1.3 billion in commitments.

  • Fundraising
  • 08 May 2015
CITIC PE, Beijing Enterprises Water to buy majority stake in Jin Cai

CITIC Private Equity has teamed up with Beijing Enterprises Water Group to acquire a majority stake in Jin Cai Holdings, a Hong Kong-listed cigarette packaging manufacturer that wants to enter the clean energy space.

  • Buyouts
  • 04 February 2015
Fortune backs Huimin's B2C-B2B switch

Huimin started out in 2012 as an online B2C platform, enabling Chinese consumers to order daily household items from small-scale supermarkets in their neighborhood. The supermarkets took care of the delivery and Huimin got a commission on each transaction....

  • Technology
  • 04 February 2015
China food-ordering platform Ele.me raises $350m

Ele.me, a Chinese online food-ordering platform, has received $350 million in a Series E round of funding from CITIC Private Equity and Sequoia Capital as well as strategic investors Tencent Holdings, JD.com and Dianping.

  • Venture
  • 28 January 2015
Chinese local supermarket O2O player gets $100m

CITIC Private Equity, Fortune Capital, GP Capital and Zhejiang Zheshang Investment Management have invested $100 million in Huimin, a Chinese B2B and B2C e-commerce platform that focuses on small-scale supermarkets.

  • Expansion
  • 28 January 2015
Hillhouse, CITIC PE commit $75m to Chinese cancer drug developer

Hillhouse Capital and CITIC Private Equity have participated in a RMB450 million ($75 million) round of funding for BeiGene, a Chinese company that develops drugs to combat cancer.

  • Greater China
  • 17 November 2014
CITIC PE exits Jialin Pharma via trade sale to Luye Pharma

CITIC Private Equity will exit a 10.26% stake in Beijing Jialin Pharmaceutical after Luye Pharma Group, a Chinese drug maker, agreed to buy a majority stake in its industry peer.

  • Greater China
  • 28 August 2014
CITIC PE scraps plans for Biosensors takeover

CITIC Private Equity has abandoned plans for a takeover of Singapore-listed Biosensors International, although it will remain an active investor in the medical device manufacturer.

  • Buyouts
  • 20 August 2014
Partial exit for PE investors as Luye Pharma raises $764m

CDH Investments, CITIC Private Equity, New Horizon Capital and GIC Private have made partial exits from Luye Pharma Group as the Chinese drug maker raised HK$5.91 billion ($764 million) through its Hong Kong IPO.

  • Exits
  • 04 July 2014
Yunfeng, CITIC PE seal $320m China dairy investment

Yunfeng Capital and CITIC Private Equity have agreed to invest at least RMB2 billion ($320.5 million) in an unlisted farming subsidiary of Chinese dairy producer Inner Mongolia Yili Industrial Group.

  • Consumer
  • 09 June 2014
CITIC PE considers Biosensors acquisition – update

CITIC Private Equity has held talks about potentially increasing its stake in Singapore-listed portfolio company Biosensors International, the medical device maker said on Wednesday.

  • Greater China
  • 20 February 2014
CITIC PE to buy medical devices firm Biosensors - report

CITIC Private Equity is said to be looking to buy full control of its Singapore-listed portfolio company Biosensors International, a medical device maker.

  • Greater China
  • 19 February 2014
234
  • About AVCJ
  • Advertise
  • Contacts
  • About ION Analytics
  • Terms of use
  • Privacy policy
  • Group disclaimer
  • RSS
  • Twitter
  • LinkedIn
  • Newsletters

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013